Trials involving Multiple Types of Cancer

Clinical Trial NameClinical Trial Full TitlePrincipal InvestigatorProject site statusClinical trials gov number
(Merck) MK-3475-587 / KEYNOTE 587A Multicenter, Open label, Phase III Extension Trial to Study the Long-term Safety and Efficacy in Participants with Advanced Tumors Who Are Currently on Treatment or in Follow-up in a Pembrolizumab TrialMcWhirter, Dr ElaineOpen to recruitmentNCT03486873
(CCTG) IND.238A Phase II Study of Durvalumab Retreatment in Patients who Discontinued Prior Checkpoint Therapy Due to Immune Related ToxicityEllis, Dr PeterOpen to recruitmentNCT03847649
(HHS) CRUSSHStereotactic body radiotherapy (SBRT) boost following urgent 3D conformal radiotherapy in the treatment of metastatic epidural spinal cord compression (SCC): A phase I feasibility trialSchnarr, Dr KaraOpen to recruitmentNCT03529708
(Tesaro) 4010-01-001 / GARNETA Phase 1 Dose Escalation and Cohort Expansion Study of TSR-042, an anti-PD-1
Monoclonal Antibody, in Patients with Advanced Solid Tumors
Reade, Dr ClareOpen to recruitmentNCT02715284
(Ayala) AL-ACC-01 / ACCURACYA Phase 2, Open-Label, Single-Arm, Multi-Center Study Of AL101 (BMS-906024) In Patients With Adenoid Cystic Carcinoma (ACC) Bearing Activating Notch MutationsHotte, Dr SebastienOpen to recruitmentNCT03691207
(Roche) BP29842AN OPEN-LABEL, MULTICENTER, DOSE-ESCALATION, PHASE IA/IB STUDY TO EVALUATE SAFETY,
PHARMACOKINETICS, AND THERAPEUTIC ACTIVITY OF RO6874281, AN IMMUNOCYTOKINE CONSISTING OF INTERLEUKIN 2 VARIANT (IL-2v) TARGETING FIBROBLAST ACTIVATION PROTEIN- (FAP), AS A SINGLE AGENT (PART A) OR IN COMBINATION WITH TRASTUZUMAB OR CETUXIMAB (PART B OR C)
Hotte, Dr SebastienOpen to recruitmentNCT02627274
(Bold Therapeutics) BOLD-100-001 / TRIO039A Phase 1b Dose Escalation Study of BOLD-100 in Combination with FOLFOX Chemotherapy in Patients with Advanced Solid TumoursMcWhirter, Dr ElaineOpen to recruitmentNCT04421820
(CCTG) IC.8COV-IMMUNO - A Randomized, Phase III Trial of Immunization with IMM-101 versus Observation for the Prevention of Severe Respiratory and COVID-19 Related Infections in Cancer Patients at Increased Risk of ExposureJuergens, Dr RosalynSuspended/On holdNCT04442048
(IMV) Immunovac / P1719-SUR-Z11A Phase 2, Open-label, Multicenter, Study of an Immunotherapeutic Treatment, DPX-Survivac in combination with Low Dose Cyclophosphamide and Pembrolizumab, in Subjects with Selected Advanced and Recurrent Solid TumoursHirte, Dr HalSuspended/On holdNCT03836352
Download PDF